BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Rossari Biotech Ltd. has announced two acquisitions in the past two months, which will help the company add 58% to revenue and 48% to Ebitda (on full merger) with total outlay of Rs 5.4 billion, yet the company will continue to remain debt free, which is comforting.
It would gain some backward integration and expand addressable market which will provide opportunity to cross-sell products among customers.
The acquisitions will also expand Rossari Biotech’s footprint in exports market, which has been limited so far.
We have put out pro-forma profit and loss post-merger with Unitop Chemicals Pvt. Ltd. and calculated attributable earnings per share for the company assuming two merger consummates.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.